Colorectal Cancer
Conditions
Brief summary
This observational, multicenter, retrospective/prospective study will evaluate the use of Avastin (bevacizumab) in clinical practice in patients with metastatic colorectal cancer. Patients having initiated first-line treatment with a fluoropyrimidine-based chemotherapy and Avastin will be followed for up to 15 months.
Interventions
None listed
Sponsors
Hoffmann-La Roche
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients, \>/= 18 years of age * Metastatic colorectal cancer * Having initiated first-line treatment with fluoropyrimidine-based chemotherapy plus Avastin between 1. September 2011 and 29. February 2012 * Availability of test fro K-RAS genotyping
Exclusion criteria
* Participation in a clinical trial during treatment with Avastin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients with Avastin treatment discontinuation due to either disease progression or Avastin-related adverse events | approximately 15 months |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients with treatment discontinuation due to other causes | approximately 15 months |
| Incidence of other causes for treatment discontinuation | approximately 15 months |
| Second-line treatments initiated | approximately 15 months |
| Progression-free survival (patients with treatment discontinuation due to disease progression or Avastin-related toxicity as compared to patients with treatment discontinuation due to other causes) | approximately 15 months |
Countries
Italy
Outcome results
None listed